{"filing":{"accession_number":"0001140361-26-028716","cik":"0001124105","ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","form":"8-K","filing_date":"2026-07-16","report_date":null,"primary_document":"ef20078088_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126028716/ef20078088_8k.htm"},"events":[{"id":18463,"run_id":16597,"accession_number":"0001140361-26-028716","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Gyre Therapeutics appointed three new directors to its Board effective August 1, 2026: Yue Xiong, Ph.D. as a Class I director, Maxwell Kirkby as a Class II director (also appointed to the Compensation Committee), and Claire Weston, Ph.D. as a Class III director (also appointed to the Audit Committee). This materially affects board composition and committee structure at the biopharmaceutical company.","company_name":"GYRE THERAPEUTICS, INC.","ticker":"GYRE","filing_date":"2026-07-16","form":"8-K","submitted_at":null,"items":[{"id":17278,"accession_number":"0001140361-26-028716","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of three new directors to Gyre's Board effective August 1, 2026: Yue Xiong, Ph.D. as a Class I director, Maxwell Kirkby as a Class II director (also appointed to the Compensation Committee), and Claire Weston, Ph.D. as a Class III director (also appointed to the Audit Committee). This is a material governance event affecting board composition and committee structure at a public biopharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T20:36:57.604837+00:00","company_name":"","ticker":null,"filing_date":""},{"id":17279,"accession_number":"0001140361-26-028716","item_number":"7.01","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of three new members to Gyre's Board of Directors, effective August 1, 2026: Yue Xiong (Chief Scientific Officer, Class I director), Maxwell Kirkby (Class II director, Compensation Committee), and Claire Weston (Class III director, Audit Committee). This is a material governance event affecting board composition and committee assignments at a public biopharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T20:36:57.604837+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":17278,"accession_number":"0001140361-26-028716","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of three new directors to Gyre's Board effective August 1, 2026: Yue Xiong, Ph.D. as a Class I director, Maxwell Kirkby as a Class II director (also appointed to the Compensation Committee), and Claire Weston, Ph.D. as a Class III director (also appointed to the Audit Committee). This is a material governance event affecting board composition and committee structure at a public biopharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T20:36:57.604837+00:00","company_name":"GYRE THERAPEUTICS, INC.","ticker":"GYRE","filing_date":"2026-07-16"},{"id":17279,"accession_number":"0001140361-26-028716","item_number":"7.01","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of three new members to Gyre's Board of Directors, effective August 1, 2026: Yue Xiong (Chief Scientific Officer, Class I director), Maxwell Kirkby (Class II director, Compensation Committee), and Claire Weston (Class III director, Audit Committee). This is a material governance event affecting board composition and committee assignments at a public biopharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T20:36:57.604837+00:00","company_name":"GYRE THERAPEUTICS, INC.","ticker":"GYRE","filing_date":"2026-07-16"}]}